Case todayBrokenOperating-margin compression · Nov 5, 2026The case · mixed · Nov 10, 2026Own TKNO if Teknova monetizes proprietary, short‑turnaround reagent manufacturing to serve >3,000 life‑science customers, translating process-driven quality and customization into durable pricing power and margin recovery as volumes scale.4 conditions1 strengthening · 2 holding · 1 weakeningNext resultsFeb 25, 2027Projected from its filing dates

TKNO at a glance

The past year

Chart

+84.1% $7.88, close Nov 18

From the highest close
−15.5%
Vs the 200-day average
+51.5%
Nov 17, 2025Daily close, Alpha TeknovaNov 18, 2026

Short interest

History

1.5M shares

Of shares outstanding
2.45%
Since the last report
−6.7%
Days to cover
1.4 days
Settled
Oct 30, 2026

Insider buying, 7 days

Filings

None filed this week

Form 4s filed
Nov 13 – Nov 19

Understand the Business

Why the Stock Moved

Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.

TKNO price history

Latest price$7.88Today+$0.23 (+3.01%)
TKNO +13.71%S&P 500 -5.00%Since first plotted close
4 hours

Loading recent earnings…

Investment thesis

What must happen next

4 MATERIAL PROPOSITIONS
  • Teknova's proprietary, configurable manufacturing processes and fast turnaround create customer stickiness and allow premium pricing, which supports higher gross profit and gross margins as volumes grow.StrengtheningMateriality: High

    gross_profit increased from 7,231,000 (FY2024) to 13,441,000 (FY2025), reversing the 2024 weakness. If true, gross margin expansion will fund operating leverage and support valuation; if false, commoditization or easy supplier substitution will compress margins and revenue economics.

    Watch: Large incumbents (e.g., Thermo Fisher / Merck Millipore) win marquee supplier agreements that shift enterprise spend away from midsized specialty suppliers.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    gross_profit increased from 7,231,000 (FY2024) to 13,441,000 (FY2025), reversing the 2024 weakness.

    Open source ↗
  • Commercial adoption of Teknova's Clinical Solutions and scale‑up of custom products will accelerate revenue growth beyond its recent low‑double‑digit pace as more development programs move to commercialization.HoldingMateriality: High

    revenue rose to 40,520,000 in FY2025 from 37,745,000 in FY2024 (positive sequential trend). Faster revenue growth reduces the likelihood that the high multiple overhangs the stock and provides the volume base needed for operating leverage; if growth stalls the premium P/S cannot be justified.

    Watch: Macro R&D spending cuts or biotech funding downturns that reduce demand for reagents.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    revenue rose to 40,520,000 in FY2025 from 37,745,000 in FY2024 (positive sequential trend).

    Open source ↗
  • As gross margin recovers, Teknova can achieve operating leverage (through fixed‑cost absorption and scaling of higher‑margin Clinical Solutions) and materially reduce operating losses toward break‑even.HoldingMateriality: Medium

    operating_income improved from (35,563,000) in FY2023 to (26,146,000) in FY2024 to (16,976,000) in FY2025 — consistent, multi‑year improvement. Turning improving gross profit into positive operating income is the step that converts product economics into sustainable free cash flow and validates the valuation; failing to do so means the company remains dependent on financing.

    Watch: Continued high SG&A or R&D spending to chase growth that offsets gross margin gains.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    operating_income improved from (35,563,000) in FY2023 to (26,146,000) in FY2024 to (16,976,000) in FY2025 — consistent, multi‑year improvement.

    Open source ↗
  • Given low reported cash relative to operating cash burn, Teknova must either achieve rapid positive operating cash flow or raise external capital; failure to do either will force dilutive financing and impair per‑share value.WeakeningMateriality: Medium

    cash declined from 42,236,000 (FY2023) to 3,708,000 (FY2024) and was 5,912,000 at FY2025 year‑end. A financing event would dilute shareholders and reset expectations; achieving self‑funding would validate the path to durable value.

    Watch: Access to capital markets or debt on reasonable terms that avoids heavy dilution.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    cash declined from 42,236,000 (FY2023) to 3,708,000 (FY2024) and was 5,912,000 at FY2025 year‑end.

    Open source ↗
Full investment case & evidence

Loading the original research archive…

Original research

Teknova's proprietary, configurable manufacturing processes and fast turnaround create customer stickiness and allow premium pricing, which supports higher gross profit and gross margins as volumes grow. If true, gross margin expansion will fund operating leverage and support valuation; if false, commoditization or easy supplier substitution will compress margins and revenue economics.

Commercial adoption of Teknova's Clinical Solutions and scale‑up of custom products will accelerate revenue growth beyond its recent low‑double‑digit pace as more development programs move to commercialization. Faster revenue growth reduces the likelihood that the high multiple overhangs the stock and provides the volume base needed for operating leverage; if growth stalls the premium P/S cannot be justified.

As gross margin recovers, Teknova can achieve operating leverage (through fixed‑cost absorption and scaling of higher‑margin Clinical Solutions) and materially reduce operating losses toward break‑even. Turning improving gross profit into positive operating income is the step that converts product economics into sustainable free cash flow and validates the valuation; failing to do so means the company remains dependent on financing.

Given low reported cash relative to operating cash burn, Teknova must either achieve rapid positive operating cash flow or raise external capital; failure to do either will force dilutive financing and impair per‑share value. A financing event would dilute shareholders and reset expectations; achieving self‑funding would validate the path to durable value.

All standing thesis claims
Original report summary

Teknova monetizes proprietary, short‑turnaround reagent manufacturing to serve >3,000 life‑science customers, translating process-driven quality and customization into durable pricing power and margin recovery as volumes scale.

Evidence assessed Nov 10, 2026. Expand each conclusion for its evidence and what would change it. Thesis evidence—not a buy or sell recommendation.

Bull case and bear case

Bull case and bear case for Alpha Teknova

Where the evidence on Alpha Teknova disagrees: Mixed on the latest evidence (Nov 10, 2026). Of its 4 thesis points, 1 strengthening, 2 holding and 1 weakening.

Bull case: what the evidence supports

  • Teknova's proprietary, configurable manufacturing processes and fast turnaround create customer stickiness and allow premium pricing, which supports higher gross profit and gross margins as volumes grow.

    sec.gov ↗

  • Commercial adoption of Teknova's Clinical Solutions and scale‑up of custom products will accelerate revenue growth beyond its recent low‑double‑digit pace as more development programs move to commercialization.

    sec.gov ↗

  • As gross margin recovers, Teknova can achieve operating leverage (through fixed‑cost absorption and scaling of higher‑margin Clinical Solutions) and materially reduce operating losses toward break‑even.

    sec.gov ↗

Bear case: what the evidence questions

  • Given low reported cash relative to operating cash burn, Teknova must either achieve rapid positive operating cash flow or raise external capital; failure to do either will force dilutive financing and impair per‑share value.

    sec.gov ↗

Company research

Research on Alpha Teknova

Thesis-Break Engine

What has broken in Alpha Teknova’s thesis

Each break OptimistFi flagged on Alpha Teknova, dated — with what has historically followed the same kind of break across the market, not a forecast for Alpha Teknova.

12 mo agonow
Trailing daily price. No thesis break has crossed here, so there is no break base rate to project.
  • Operating-margin compression

Early warning

The break condition read on the trailing twelve months through Alpha Teknova’s latest quarterly report, ahead of the annual figure it is written on.

  • Operating-margin compression, trailing 12 months

    Across all companies, this kind of early warning has happened 2,641 times before. Those stocks trailed the market by a median of 1% over the next six months, and 36% of them trailed it by 10 points or more.

How the Thesis-Break Engine works →Historical outcomes are measured against the market after past breaks of the same kind, across all companies. Not a prediction.

MARKET + FINANCIAL SNAPSHOT

The numbers behind the thesis

Sourced from filings and market data

What Changed

  1. Mixed
    Reported results of operations (earnings release).

    Alpha Teknova filed an SEC 8-K on 2026-11-04: Reported results of operations (earnings release). It is a dated development that tests the current thesis.

  2. Mixed
    Reported results of operations (earnings release).

    Alpha Teknova filed an SEC 8-K on 2026-10-21: Reported results of operations (earnings release). It is a dated development that tests the current thesis.

  3. Mixed
    Reported results of operations (earnings release).

    Alpha Teknova filed an SEC 8-K on 2026-08-05: Reported results of operations (earnings release). It is a dated development that tests the current thesis.

Risks / falsifiers

What could break the thesis

  • Large incumbents (e.g., Thermo Fisher / Merck Millipore) win marquee supplier agreements that shift enterprise spend away from midsized specialty suppliers.
  • Macro R&D spending cuts or biotech funding downturns that reduce demand for reagents.
  • Continued high SG&A or R&D spending to chase growth that offsets gross margin gains.
  • Access to capital markets or debt on reasonable terms that avoids heavy dilution.

TKNO news

Loading headlines…

Financial statements

TKNO income statement

Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.

TKNO: quick answers

When does Alpha Teknova (TKNO) report earnings next?
Alpha Teknova's next results are projected for February 25, 2027, from the dates of its own results filings with the SEC. The company has not confirmed the date. It last reported on November 4, 2026. Earnings calendar
What is TKNO's short interest?
As of October 30, 2026, 1.5M TKNO shares were sold short, 2.45% of its shares outstanding, down 6.7% from the count before. At the stock's average daily volume that is 1.4 days to cover. FINRA publishes the count twice a month. TKNO short interest history
ScoutJUST THIS STORY

LET’S MAKE THIS USEFUL · 1 OF 5

How would you like me to explain this?

Tell me what you want from this read. Start with a quick note, then adjust the details. Your other stories stay as they are.

We’ll remember your view of this story. The published article stays unchanged.

THIS STORY’S READING VIEWStandard · The whole picture

Clear explanations with context. Both sides of the evidence.